Has Michael Stempel, DPM received payments from drug or device companies?

Yes. Drug and device makers reported $5,110 in general payments to Michael Stempel, DPM across 165 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Michael Stempel, DPM did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Michael Stempel, DPM come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Michael Stempel, DPM

Podiatrist · Washington, DCNPI 1043306145

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 97.8% of the total across 165 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 27 manufacturers, the largest accounting for just 21.4% — the pattern of someone who eats at a lot of different presentations. Among podiatrist clinicians in DC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$5,110in general payments, 2019–2025

Across 165 payments — averaging $30.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Organogenesis Inc.$1K
Reapplix Inc.$846
Integra Lifesciences Corporation$551
Kerecis Limited$401
Stryker$313
Smith+Nephew$304
plus $2K from 21 others

What the payments were for

Speaking & faculty fees$1152%
Food & beverage$4,99598%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Organogenesis Inc.	45	$1,095
Reapplix Inc.	17	$846
Integra Lifesciences Corporation	20	$551
Kerecis Limited	6	$401
Stryker(2 entities)	6	$313
Smith+Nephew	11	$304
Tactile Systems Technology Inc	17	$303
Amgen	2	$138
Convatec Inc.	6	$133
Bioventus LLC	1	$132
Orthofix Medical, Inc.	2	$116
KCI USA, Inc.	4	$102
Polynovo North America LLC	4	$90
Molnlycke Health Care US, LLC	3	$84
Mimedx Group, Inc.	3	$69
Acera Surgical, Inc.	2	$56
ETS Wound Care LLC	2	$55
Urgo Medical North America, LLC	2	$47
Hydrofera LLC	2	$46
AbbVie	2	$45
Aroa Biosurgery Incorporated	1	$41
Solventum Corporation	2	$40
Polarityte, Inc.	1	$32
Paratek Pharmaceuticals, Inc.	1	$21
Musculoskeletal Transplant Foundation Inc.	1	$17
Hartmann USA, Inc.	1	$17
Paragon 28, Inc.	1	$15

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,110 in reported general payments places this provider in the 95th percentile of 24 podiatrist providers in District of Columbia.

See all podiatrist providers in District of Columbia →

Medicare billing

Part B allowed, 2024

$120,823

Medicare patients

365

Services billed

1,307

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Naloxone Hcl	19	$1,002
Ammonium Lactate	24	$542
Ketoconazole	28	$492
Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip	13	$315
Naproxen	16	$173
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim	11	$160

Paid to pharmacies, not to this prescriber.

Other podiatrist in Washington

Kevin JeffersonWashington$94K
Nadav AvnerWashington$4K
Farah SiddiquiWashington$2K
Ian BeiserWashington$2K
Lee FirestoneWashington$2K
Kirk GeterWashington$1K
Arnold RavickWashington$1K
Sheldon LapsWashington$1K
Lubrina BryantWashington$951
James GirolamiWashington$718

See the full list for District of Columbia →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →